BiotechTube
Home/Biomendics/Mike Kessel, MBA
MK

Mike Kessel, MBA

Board Member

Biomendics

Therapeutic Areas

Rare Dermatologic Disorders

Biomendics Pipeline

DrugIndicationPhase
MTORX™ (Lead Program)Epidermolysis Bullosa Simplex (EBS)Phase 2
MTORX™ PlatformEpidermolytic Ichthyosis (EI)Preclinical

Leadership Team at Biomendics

KM
Karen M. McGuire, PhD
CEO, Founder
View full Biomendics profile